Effects of treatment with liraglutide 3.0 mg in subjects with BMI < 35 and BMI ≥35 kg/m2: subgroup analysis of the SCALE Obesity and Prediabetes 56-week trial

This post-hoc analysis investigated effects of liraglutide 3.0 mg in those with BMI < 35 v ≥35 kg/m2 at baseline in the SCALE Obesity and Prediabetes trial.3731 adults (mean ± SD: age 45.1 ± 12.0y; BMI 38.3 ± 6.4 kg/m2; male 21.5%; with prediabetes 61.2%) were randomized 2:1 to liraglutide 3.0 mg or placebo as adjunct to diet and exercise (D&E) for 56 weeks (W). Treatment effect across baseline BMI subgroups was evaluated by testing interaction between baseline BMI subgroup and treatment (BMI < 35: liraglutide 3.0 mg 856 patients; placebo 423; BMI ≥35: liraglutide 3.0 mg 1581; placebo 802). Baseline demographics…